Suppr超能文献

益生菌安全性论证——综述

Demonstration of safety of probiotics -- a review.

作者信息

Salminen S, von Wright A, Morelli L, Marteau P, Brassart D, de Vos W M, Fondén R, Saxelin M, Collins K, Mogensen G, Birkeland S E, Mattila-Sandholm T

机构信息

University of Turku, Department of Biochemistry and Food Chemistry, Finland.

出版信息

Int J Food Microbiol. 1998 Oct 20;44(1-2):93-106. doi: 10.1016/s0168-1605(98)00128-7.

Abstract

Probiotics are commonly defined as viable microorganisms (bacteria or yeasts) that exhibit a beneficial effect on the health of the host when they are ingested. They are used in foods, especially in fermented dairy products, but also in pharmaceutical preparations. The development of new probiotic strains aims at more active beneficial organisms. In the case of novel microorganisms and modified organisms the question of their safety and the risk to benefit ratio have to be assessed. Lactic acid bacteria (LAB) in foods have a long history of safe use. Members of the genera Lactococcus and Lactobacillus are most commonly given generally-recognised-as-safe (GRAS) status whilst members of the genera Streptococcus and Enterococcus and some other genera of LAB contain some opportunistic pathogens. Lactic acid bacteria are intrinsically resistant to many antibiotics. In many cases resistances are not, however, transmissible, and the species are also sensitive to many clinically used antibiotics even in the case of a lactic acid bacteria- associated opportunistic infection. Therefore no particular safety concern is associated with intrinsic type of resistance. Plasmid-associated antibiotic resistance, which occasionally occurs, is another matter because of the possibility of the resistance spreading to other, more harmful species and genera. The transmissible enterococcal resistance against glycopeptide antibiotics (vancomycin and teicoplanin) is particularly noteworthy, as vancomycin is one of the last effective antibiotics left in the treatment of certain multidrug-resistant pathogens. New species and more specific strains of probiotic bacteria are constantly identified. Prior to incorporating new strains into products their efficacy should be carefully assessed, and a case by case evaluation as to whether they share the safety status of traditional food-grade organisms should be made. The current documentation of adverse effects in the literature is reviewed. Future recommendations for the safety of already existing and new probiotics will be given.

摘要

益生菌通常被定义为摄入后对宿主健康具有有益作用的活微生物(细菌或酵母)。它们被用于食品中,尤其是发酵乳制品,也用于药物制剂中。开发新的益生菌菌株旨在获得更具活性的有益微生物。对于新型微生物和经过改造的微生物,必须评估其安全性以及风险效益比。食品中的乳酸菌有着长期安全使用的历史。乳酸球菌属和乳酸杆菌属的成员大多被普遍认为是安全的(GRAS),而链球菌属和肠球菌属的成员以及乳酸菌的其他一些属包含一些机会致病菌。乳酸菌对许多抗生素具有内在抗性。然而,在许多情况下,抗性是不可传播的,即使在乳酸菌相关的机会性感染情况下,这些菌种对许多临床使用的抗生素也很敏感。因此,与内在抗性类型无关的特殊安全问题。偶尔出现的质粒相关抗生素抗性则是另一回事,因为抗性有可能传播到其他更有害的菌种和属。肠球菌对糖肽类抗生素(万古霉素和替考拉宁)的可传播抗性尤其值得关注,因为万古霉素是治疗某些多重耐药病原体的最后一种有效抗生素之一。新的益生菌种类和更具特异性的菌株不断被发现。在将新菌株纳入产品之前,应仔细评估其功效,并逐案评估它们是否具有传统食品级微生物的安全地位。本文回顾了文献中目前关于不良反应的记录。并将给出关于现有和新益生菌安全性的未来建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验